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ABSTRACT 
 
Background:  Esophageal carcinoma is an aggressive disease that is often treated with 
neoadjuvant therapy followed by surgical resection.  Diabetes mellitus (DM) has been 
associated with reduced efficacy of chemoradiation (CRT) in other gastrointestinal 
cancers.  The goal of this study was to determine if DM affects response to neoadjuvant 
CRT in the management of gastroesophageal carcinoma. 
Methods: We retrospectively reviewed the esophageal cancer patient databases and 
subsequently analyzed those patients who received neoadjuvant CRT followed by 
surgical resection at two institutions, Thomas Jefferson University (TJUH) and Fox 
Chase Cancer Center (FCCC).  Comparative analyses of rates of pathologic complete 
response rate (pCR) and pathologic downstaging in DM patients versus non-DM patients 
was performed. 
Results:  Two hundred and sixty patients were included in the study; 36 patients had DM 
and 224 were non-diabetics.  The average age of the patients was 61 years (range 24-84 
years).  The overall pCR was 26%.  The pCR rate was 19% and 27% for patients with 
DM and without DM, respectively (p= 0.31).  Pathologic downstaging occurred in 39% 
of study patients, including of 33% of DM patients and 40% of non-DM patients 
(p=0.42). 
Conclusions:  Although the current analysis does not demonstrate a significant reduction 
in pCR rates or pathologic downstaging in patients with DM, the observed trend suggests 
that a potential difference may be observed with a larger patient population.  Further 
studies are warranted to evaluate the influence of DM on the effectiveness of neoadjuvant 
CRT in esophageal cancer. 
INTRODUCTION 
 Over the past two decades, diabetes mellitus (DM) has become endemic 
throughout the United States and globally.  It is estimated that by the year 2010, 221 
million people will be affected with diabetes; up from 124 million in 1997 1.  Because an 
increasing number of cancer patients will also carry the diagnoses of DM, it is important 
to fully understand the implications that DM has on the prognosis and treatment of cancer 
treatment.   
 In 2004, Coughlin et al, in a large prospective cohort study, found that diabetes 
mellitus was an independent predictor of mortality from multiple cancers, including 
cancer of the colon, breast, liver, pancreas, and bladder.  Diabetes is often considered to 
be a common risk factor for esophageal adenocarcinoma. A recent meta-analyses 
comparing overall survival in all cancer patients with and without preexisting diabetes  
found that diabetic patients are at an increased risk for long-term, all-cause mortality 
compared with non-diabetic patients 2.   
Esophageal cancer is the eighth most common cause of cancer worldwide 3.  It 
often presents at an advanced stage and therefore tends to be incurable.  For resectable 
disease, surgery is the gold standard treatment.  Even with improving resection rates and 
decreasing postoperative mortality rates, 5-year survival after esophagectomy is only 25-
35% 3-6.  Neoadjuvant chemotherapy and radiation therapy are often added to the 
treatment of  patients with resectable esophageal cancer, although the benefits remain 
small 7-9.   
 Response to neoadjuvant therapy is a valuable marker of tumor biology and 
prognosis.  Numerous studies have shown that the subset of esophageal cancer patients 
that are able to achieve a complete pathologic response (pCR) after neoadjuvant therapy 
have significantly better outcomes 10-14 .  It is therefore imperative to determine if there 
are any patient related factors that may affect individual ability to achieve pCR.  In 2008, 
Caudle et al demonstrated that although diabetic patients had a similar rate of 
downstaging after neoadjuvant therapy compared to non-diabetics, no diabetic patients 
achieved a pCR.  The authors concluded that neoadjuvant therapy in rectal cancer is less 
effective in diabetic patients than in non-diabetic patients. The goal of the current study 
was to determine if diabetes mellitus had an influence on the rate of pCR and tumor 
downstaging in the treatment of esophageal cancer.  To our knowledge this relationship 
in esophageal cancer has never been reported in the literature. 
 
METHODS 
 Institutional Review Board approved esophagectomy databases at both 
institutions were searched to identify patients with esophageal cancers who received CRT 
followed by surgical resection.  Dates of surgical resections included the time periods of 
1994-2006 (TJUH) and 1992-2002 (FCCC).  Medical records were reviewed, including 
office notes, operative dictations and pathology reports.  Data recorded included 
demographics, medical history, length of stay, chemotherapeutic regimen, type of 
esophagectomy, completeness of resection, histologic diagnosis, tumor location, initial 
stage, pathologic stage, pathologic complete response, total lymph nodes, number of 
positive lymph nodes, time to recurrence and survival.  Patients were classified as having 
DM or not based on past medical history as listed in hospital or clinic notes as well as 
examination of medication lists (including oral hypoglycemic agents and/or insulin) 
during the time that they underwent CRT. 
 Pretreatment or initial stage was determined using a combination of computed 
tomography (CT) scan, endoscopic ultrasound (EUS) and sometimes positron emission 
tomography (PET) scans.  Staging was by the American Joint Committee on Cancer 
(AJCC) TNM staging, sixth edition.  The neoadjuvant chemotherapy most often included 
a 5-fluoruracil, taxol and platinum (cisplatinum or carboplatinum) regimen, in 
concurrence with phase I and II trials at the two institutions 15, 16.  These regimens were 
most commonly given concurrently with external beam radiation therapy to a dose of 45 
Gy.  The individual surgical method was left to the discretion of the operating surgeon.  
Surgery was performed approximately four to six weeks after the completion of CRT and 
re-staging to ensure no metastatic disease.  Post-treatment staging was determined by 
pathologic review.  A pCR was defined as no residual tumor cells in the surgical 
specimen including the primary site and surrounding lymph nodes.  Downstaging was 
defined as patients whose tumors underwent significant regression down to T1 tumors 
with no nodal involvement.  Chi-square test was used as a comparative analysis of rates 
of pathologic complete response rate (pCR) and pathologic downstaging in DM patients 
versus non-DM patients. 
RESULTS 
 Two hundred and sixty patients were included in this retrospective study.  Thirty-
six (13.8%) patients had DM and 224 (86.2%) were nondiabetics (non-DM).  The 
average age for the overall patient population was 61 years (61 years for DM group 
(range=41-78) and 60 years (range=24-84) for non-DM group).    Overall, the male to 
female ratio was 5.6:1.  Of note, the male to female ratio was 17:1 in the DM group and 
5.5:1 in the non-DM group.  The location of the tumors was not appreciably different 
between the two patient groups.  The majority of tumors were located at the distal 
esophagus and gastroesophageal junction (Table 1).  All patients in both groups 
completed neoadjuvant therapy.  Surgical resection followed neoadjuvant therapy in all 
patients in this study.  
  The groups did not have statistically different differences in the initial clinical 
stage or the pathological stage; the majority of patients in both groups presented with 
stage 2 disease.  There were 12 patients with initial stage IVa disease.  The majority of 
stage 2 patients were those with T3N0 disease.  Among the non-diabetic patients, there 
were 44 with T2, 149 with T3, and 9 with T4 disease. In contrast there were 7 T2, 27 T3, 
and one T4 patient in the diabetic group.  There were no significant differences in pre-
treatment nodal staging either with the non-diabetics group having 21% Nx, 36% N0, and 
43% N1, and the diabetic group having 27%Nx, 40% N0, and 33% N1.   
 There were a total of 44 patients with squamous cell carcinoma (SCC, 17%).  Of 
these 44, only one was diabetic, and this patient did not have a partial or complete 
response.  Among the 44 patients with SCC, the pCR rate was 32% (14 of 44).  A total of 
43% of SCC patients achieved a significant partial or complete response.  By contrast, the 
majority of patients in this series had adenocarcinoma (n=216, 83%) which reflects 
national trends. The pCR rate among patients with adenocarcinoma was 25% and the 
significant responder rate was 39%. 
Among the patients with DM, there were only six patients who required insulin 
and the rest (n=30) patients taking oral hypoglycemic agents.  Unfortunately due to the 
retrospective nature of this study, it is difficult to examine glycemic control.  HgA1c 
levels were not routinely evaluated and therefore are not available to examine.  Most 
patients received long-term continuous infusion 5-FU at a dosage of 225 mg/m2/day 
during the entire course of radiation therapy.  As part of various ongoing clinical trials 
many patients received additional chemotherapy agents.  These included paclitaxel (doses 
ranging from 30 to 60 mg/m2 given weekly), carboplatinum (AUC=5, given on day 1 and 
29), and cisplatinum (75mg/m2).    
After appropriate neoadjuvant therapy, 19.4% of the diabetic patients and 26.8% 
of the nondiabetic patients had no detectable residual disease in the pathologic specimen.  
In the diabetic group, 11 patients (30%) had stage 0 or 1 residual disease, while 89 (40%) 
of the non-diabetics had stage 0 or 1 residual disease (p= 0.36).  In the diabetic group, 
33.3% had positive lymph nodes, while in the nondiabetic group 37.7% had positive 
lymph nodes (Table 2). 
  The overall rate of achieving a complete pathologic response for the entire 
patient population was 26%.  There was a trend for a decrease in the rate of pCR in the 
diabetic group, 19% versus 27% in the nondiabetic group.  This trend was not statistically 
significant (p= 0.31).     
 Overall, pathologic downstaging occurred in 39% of study patients.  The rate of 
pathologic downstaging was lower in diabetic patients (33%) compared to nondiabetic 
patients (40%), although this was not statistically significant (p= 0.42). 
 
 
 
 
 
DISCUSSION  
 Preoperative CRT followed by surgical resection is the treatment regimen 
employed in most patients with resectable esophageal cancer.  Achieving pCR and node 
negative status are two major determinants of outcome following neoadjuvant CRT 14, 17.  
Our analysis does not demonstrate a significant difference between diabetic and 
nondiabetic patients in terms of achieving pCR and pathologic downstaging.  However, 
the observed trend does suggest that diabetic patients have an inferior response to 
neoadjuvant therapy when compared to nondiabetic patients.  In this study, diabetic 
patients had a lower rate of both pCR and pathologic downstaging, although neither was 
statistically significant.   The data reported by Caudle et al, demonstrated that 
neoadjuvant therapy was less effective in achieving pCR in diabetic rectal cancer patients 
than in their nondiabetic counterparts.  Although the exact mechanism remains unknown, 
their data, and the data presented in this study, do implicate diabetes as a predictor of 
poor response to neoadjuvant therapy 18.   
 Unlike with colorectal cancers, there is no published data that illustrates a similar 
relationship between DM and esophageal cancer 19.  There are ample data that support 
that diabetes is an independent patient characteristic predictive of increased morbidity 
and mortality after esophagectomy 6, 20-22.  The incidence of esophageal cancer is 
increasing 23 and a large majority of these patients are treated with CRT.  Unfortunately 
the mortality rate of esophageal cancer remains high.  It is therefore of paramount 
importance to determine the factors that influence patient response to CRT.  The exact 
mechanism of the relationship between diabetes and decreased response to CRT remains 
unknown.  Possible explanations for the negative effect that diabetes has on cancer 
patients’ ability to appropriately respond to CRT include the molecular effects of insulin 
and insulin-like growth factor on tumor growth, and the relationship between the effects 
of DM on the body and the ability to effectively deliver neoadjuvant treatment.     
 Diabetes mellitus, especially Type II, is often coupled with obesity and 
hyperinsulinemia.  Hyperinsulinemia is known to cause an increase in insulin-like growth 
factor (IGF), a well-studied survival factor for cancer cells.  In 2002 Liu et al published 
in vitro work showing that IGF, which is upregulated in cancer patients, is able to 
stimulate tumor growth.  IGF was also shown to prevent the expected apoptosis in 
esophageal cancer cells that had been treated with commonly used chemotherapeutic 
drugs such as 5-fluorouracil and cisplatin 24.  This preclinical work is especially relevant 
because hyperinsulinemia and increased levels of IGF in DM and non-DM patients have 
been shown to be a risk factor for developing gastroesophageal adenocarcinoma as well 
as other gastrointestinal cancers 25, 26.  In this retrospective study we did not measure 
insulin or IGF levels in our patients or in their tumor specimens.  Future prospective 
clinical studies that include this information have the potential to clarify the relationship 
between DM, hyperinsulinemia, IGF levels and response to neoadjuvant therapy. 
 A more tangible yet hypothetical possibility to explain the relationship between 
DM and patient response to neoadjuvant therapy is the long-term effect that diabetes has 
on patients’ microvasculature.  The relative hypoxic environment created by vascular 
disease may reduce the effectiveness of radiation therapy.  Additionally, the 
compromised blood flow could limit the delivery of chemotherapy.   DM contributes to 
the development of microvascular disease as has been shown by multiple studies to 
contribute to morbidity and mortality in patients undergoing esophagectomy 6, 20-22.   The 
complications caused by microvasculature disease could also lead to decreased delivery 
of radiosensitizing drugs.  This may compound the hypoxic environment of the tumor and 
diminish the efficacy of radiation therapy.  For example, microvascular disease is felt to 
contribute to the higher rate of anastomotic leak seen in diabetic patients after rectal 
surgery 27.  Additionally, in cervical cancer, rectal dysfunction is increased in diabetic 
patients after radiotherapy in comparison to non-diabetics28.  These functional 
consequences may help to explain the role of microvascular disease in the decreased drug 
delivery to the tumor and therefore a decreased response to therapy. 
 There are numerous factors that will need to be further studied as we attempt to 
elucidate this relationship.  If increased insulin levels do indeed promote tumor growth, 
then it would seem important that glucose levels be tightly controlled during neoadjuvant 
therapy.  Due to the retrospective nature of this study, HbA1c levels were not routinely 
followed in these patients.  Also, patients undergoing neoadjuvant therapy for esophageal 
cancer often have severe dysphagia at the commencement of therapy and will have 
derangements in their diet—either decreased calories or an increased carbohydrate load 
in those patients receiving jejunostomy tube feeds.  These serve to cause wide 
fluctuations in glucose and insulin levels.  Prospective study of these phenomena will be 
important.   
 The results of this study suggest diabetic patients with esophageal cancer have a 
decreased ability to respond to CRT.  This is the first study which demonstrates that there 
could be a relationship between diabetes mellitus and response to neoadjuvant 
chemoradiation; this study raises a hypothesis that warrants future investigations with a 
larger patient population.   
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TABLE 1—Demographics 
  Diabetic Patients Nondiabetic Patients 
 
  
Total number 36 224 
Average age 61 (range 41-78)  60 (range 24-84) 
Gender (male:female 
ratio) 
17:1 5.5:1 
Location of tumor   
     Proximal 0 (0%) 2 (0.9%) 
     Middle 2 (5.6%) 26 (11.6 %) 
     Distal 16 (44.4%) 92 (41%) 
     GE Junction 14 (38.9%) 84 (37.5%) 
     Cardia 4 (11.1%) 20 (8.9%) 
Surgical Procedure   
     Ivor-Lewis 19 (52.8%) 107 (47.8%) 
     Transhiatal 8 (22.2%) 46 (20.5%) 
  
     3-Hole 5 (13.9%) 62 (27.7%) 
     Other 4 (11.1%) 9 (4.0%) 
 
  
TABLE 2—Patient Staging  
 
 Diabetic Patients 
(n=36) 
Nondiabetic Patients 
(n=224) 
Initial clinical 
Stage* 
  
     1 0 (0%) 2 (0.96%) 
     2 21 (61.8%) 124 (59.6%) 
     3 11 (32.4%) 72 (34.6%) 
     4 2 (5.9%) 10 (4.8%) 
Pathologic Stage   
     No Residual     
      Disease 
7 (19.4%) 60 (26.8%) 
     1 4 (11.1%) 29 (13.0%) 
     2 14 (38.9%) 72 (32.1%) 
     3 10 (27.8%) 49 (21.9%) 
     4 1 (2.8%) 14 (6.3%) 
Positive lymph 
node status** 
12 (33.3%) 83 (37.7%) 
* Data unavailable for 2 diabetic and 16 nondiabetic patients 
** Data unavailable for 4 nondiabetic patients 
 
TABLE 3—Response to chemoradiotherapy 
 
 Diabetic Patients 
(n=36) 
Nondiabetic Patients 
(n=224) 
p value 
pCR* 7/36 (19.4%) 60/223 (27%) 0.42 
Pathologic 
downstaging 
12/36 (33%) 90/224 (40%) 0.47 
* Data unavailable for 1 nondiabetic patient 
 
 
